Compare Diageo plc (DEO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Sana Biotechnology Inc — how do they compare? Diageo plc trades at $86.83 (market cap $47.67B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Diageo plc is far larger — about 57× Sana Biotechnology Inc's market cap, and Diageo plc pays a 2.3% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Sana Biotechnology Inc for 23 Days on average.
| DEO | SANA | |
|---|---|---|
Market Cap | $47.67B | $836.71M |
Volume | 893,372 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $5.92 |
52-Week Low | $72.47 | $2.68 |
Typical Hold Time | 66 Days | 23 Days |
Enterprise Value | $68.09B | $749.96M |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.73, up 2.36% with bullish technical indicators and strong analyst support. The company demonstrates solid fundamentals with consistent earnings beats, a 15.82% ROE, and positive cash flow generation. Recent corporate developments include a new CFO appointment and marketing initiatives across key brands, though revenue declined to $19.6B in 2026 with margin compression.
The stock presents a compelling turnaround opportunity with analyst consensus favoring bullish sentiment (48.65% buy ratings). Key catalysts include cost-saving initiatives and brand revitalization, while risks involve US market challenges, regulatory scrutiny in India, and ongoing margin pressure. The current valuation at 27.91 P/E appears reasonable given the growth potential.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
